I
INNPF
vs
S&P 500
S&P 500
Over the past 12 months, INNPF has significantly outperformed S&P 500, delivering a return of +4 817% compared to the S&P 500's +12% growth.
Stocks Performance
INNPF vs S&P 500
Performance Gap
INNPF vs S&P 500
Performance By Year
INNPF vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Innocan Pharma Corp
Glance View
InnoCan Pharma Corp. focuses on the development and sale of CBD-integrated pharmaceuticals including topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The company operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The firm is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
